MENU
+Compare
FTXH
ETF ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$26.92
Change
-$0.20 (-0.74%)
Net Assets
14.81M

FTXH stock forecast, quote, news & analysis

Category: @Health
FTXH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for FTXH with price predictions
Jan 08, 2025

FTXH's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for FTXH turned positive on January 06, 2025. Looking at past instances where FTXH's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FTXH's RSI Indicator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where FTXH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FTXH advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on FTXH as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTXH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FTXH entered a downward trend on December 31, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), ZOETIS (NYSE:ZTS), Regeneron Pharmaceuticals (NASDAQ:REGN).

Industry description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals TM Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Market Cap

The average market capitalization across the First Trust Nasdaq Pharmaceuticals ETF ETF is 57.37B. The market cap for tickers in the group ranges from 1.24B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is ARVN at 1.24B.

High and low price notable news

The average weekly price growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF ETF was 0%. For the same ETF, the average monthly price growth was 0%, and the average quarterly price growth was -4%. ITCI experienced the highest price growth at 33%, while VKTX experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF ETF was 1%. For the same stocks of the ETF, the average monthly volume growth was -13% and the average quarterly volume growth was 37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 78
Price Growth Rating: 59
SMR Rating: 69
Profit Risk Rating: 65
Seasonality Score: -13 (-100 ... +100)
View a ticker or compare two or three
FTXH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Wheaton
Phone
N/A
Web
www.ftportfolios.com